|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2007-11-12
|
|
pubmed:abstractText |
We evaluated the possible use of prostate-specific antigen doubling time (PSA-DT) before chemotherapy initiation as a surrogate marker of survival in hormone-refractory prostate cancer (HRPC) patients.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
1569-8041
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
18
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1828-33
|
|
pubmed:meshHeading |
pubmed-meshheading:17846024-Aged,
pubmed-meshheading:17846024-Aged, 80 and over,
pubmed-meshheading:17846024-Analysis of Variance,
pubmed-meshheading:17846024-Antineoplastic Agents, Hormonal,
pubmed-meshheading:17846024-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:17846024-Cohort Studies,
pubmed-meshheading:17846024-Confidence Intervals,
pubmed-meshheading:17846024-Drug Resistance, Neoplasm,
pubmed-meshheading:17846024-Humans,
pubmed-meshheading:17846024-Immunohistochemistry,
pubmed-meshheading:17846024-Male,
pubmed-meshheading:17846024-Middle Aged,
pubmed-meshheading:17846024-Multivariate Analysis,
pubmed-meshheading:17846024-Neoplasm Metastasis,
pubmed-meshheading:17846024-Neoplasm Staging,
pubmed-meshheading:17846024-Probability,
pubmed-meshheading:17846024-Prognosis,
pubmed-meshheading:17846024-Prostate-Specific Antigen,
pubmed-meshheading:17846024-Prostatic Neoplasms,
pubmed-meshheading:17846024-Retrospective Studies,
pubmed-meshheading:17846024-Risk Assessment,
pubmed-meshheading:17846024-Survival Analysis,
pubmed-meshheading:17846024-Time Factors,
pubmed-meshheading:17846024-Treatment Outcome,
pubmed-meshheading:17846024-Tumor Markers, Biological
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patients.
|
|
pubmed:affiliation |
Georges Pompidou European Hospital, Medical Oncology Department, Paris, France. stephane.oudard@egp.aphp.fr
|
|
pubmed:publicationType |
Journal Article,
Multicenter Study
|
